NCT00991510 - Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions

Stable Renal Transplant Recipients

Interventions

DRUG

mycophenolate mofetil (Myfenax)

Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.

DRUG

mycophenolate mofetil (Cellcept)

Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.